BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 27
• 28
• 29
• 30

• FDA

  Helsinn Integrative Care Wins FDA Nod for Medical Device Xonrid Gel

  December 1, 2016

   · 

  4 min read
• Pharm Country

  AzurRx BioPharma CEO Provides Shareholders With A “State Of The Union” Communication

  December 1, 2016

   · 

  5 min read
• Drug Development

  Cyclacel Pharma’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia

  December 1, 2016

   · 

  6 min read
• Pharm Country

  Inovio Pharma Awarded $6.1 Million Sub-Grant Through Wistar Institute To Develop DNA-Based Monoclonal Antibodies Against Zika Virus

  December 1, 2016

   · 

  8 min read
• BioCapital

  PetLife Pharma Updates Shareholders On The Company Progress With Vitalzul Studies And Additional Product Offerings

  December 1, 2016

   · 

  3 min read
• Drug Development

  Kura Oncology Presents Preclinical Data On KO-947 And Menin-MLL Inhibitor Program At The EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

  December 1, 2016

   · 

  5 min read
• Drug Development

  Heat Biologics Presents Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting

  December 1, 2016

   · 

  6 min read
• Drug Development

  Global Blood Therapeutics Announces Upcoming Investor Webcast To Review GBT440 Data Being Presented At American Society of Hematology That Support Sickle Cell Disease Program

  December 1, 2016

   · 

  3 min read
• Drug Development

  Amgen And Cytokinetics Release: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure

  December 1, 2016

   · 

  20 min read
• Drug Development

  Cellectar Biosciences Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies

  December 1, 2016

   · 

  8 min read